Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

Merck’s (NYSE:MRK) human papillomavirus (HPV) vaccine Gardasil 9 has met key efficacy goals in a pivotal late-stage trial involving Japanese males ages 16 to 26 years. The Phase 3 V503-064 trial ...

Human papillomavirus (virus like particle, 9-valent) vaccine is under clinical development by Merck and currently in Phase II for Human Papillomavirus Infections.

RAHWAY, N.J. - Merck & Co., Inc. (NYSE:MRK), a global healthcare company, announced today that its Phase 3 trial for the GARDASIL®9 HPV vaccine has met its primary and secondary endpoints in a ...

NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...